A phase III, single center, open label, uncontrolled study to evaluate the immunogenicity, safety and tolerability, of the Chiron meningococcal C conjugate vaccine when administered to healthy premature and non premature children at 3, 5, 11 months of age concomitantly with a hexavalent infant vaccine

Trial Profile

A phase III, single center, open label, uncontrolled study to evaluate the immunogenicity, safety and tolerability, of the Chiron meningococcal C conjugate vaccine when administered to healthy premature and non premature children at 3, 5, 11 months of age concomitantly with a hexavalent infant vaccine

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Mar 2007

At a glance

  • Drugs Meningococcal vaccine group C conjugate (Primary)
  • Indications Meningococcal group C infections
  • Focus Adverse reactions; Pharmacodynamics; Registrational
  • Sponsors Chiron Corporation; Novartis
  • Most Recent Events

    • 05 Nov 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top